Sign In
6 Jan 2020 08:00
ANNOUNCEMENT TO BE MADE BY THE AIM APPLICANT PRIOR TO ADMISSION IN ACCORDANCE WITH RULE 2 OF THE AIM RULES FOR COMPANIES ("AIM RULES") | ||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY NAME: | ||||||||||||||||||||||||||||||||||||||||||||||||
Open Orphan plc
| ||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY REGISTERED OFFICE ADDRESS AND IF DIFFERENT, COMPANY TRADING ADDRESS (INCLUDING POSTCODES) : | ||||||||||||||||||||||||||||||||||||||||||||||||
Registered Office:
PO Box W1J 6BD, Berkley Square House, 2nd Floor, Mayfair, London, W1J 8DJ
Trading Offices:
19 Railway Road, Dalkey, Dublin, Ireland Queen Mary BioEnterprises (QMB) Innovation Centre, 42 New Road, London, E1 2AX
| ||||||||||||||||||||||||||||||||||||||||||||||||
COUNTRY OF INCORPORATION: | ||||||||||||||||||||||||||||||||||||||||||||||||
England and Wales
| ||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY WEBSITE ADDRESS CONTAINING ALL INFORMATION REQUIRED BY AIM RULE 26: | ||||||||||||||||||||||||||||||||||||||||||||||||
www.openorphan.com
| ||||||||||||||||||||||||||||||||||||||||||||||||
COMPANY BUSINESS (INCLUDING MAIN COUNTRY OF OPERATION) OR, IN THE CASE OF AN INVESTING COMPANY, DETAILS OF ITS INVESTING POLICY). IF THE ADMISSION IS SOUGHT AS A RESULT OF A REVERSE TAKE-OVER UNDER RULE 14, THIS SHOULD BE STATED: | ||||||||||||||||||||||||||||||||||||||||||||||||
This is a reverse takeover under Rule 14.
Open Orphan is a Clinical Research Organisation that specialises in rare and orphan drugs. The headquarters are in Dublin, Ireland and the company also has offices in the UK, France, the Netherlands and Germany.
| ||||||||||||||||||||||||||||||||||||||||||||||||
DETAILS OF SECURITIES TO BE ADMITTED INCLUDING ANY RESTRICTIONS AS TO TRANSFER OF THE SECURITIES (i.e. where known, number and type of shares, nominal value and issue price to which it seeks admission and the number and type to be held as treasury shares): | ||||||||||||||||||||||||||||||||||||||||||||||||
Number of ordinary shares of 0.1 pence each in nominal value ("Ordinary Shares") for which Admission will be sought: TBC
There are no restrictions as to the transferability of the Ordinary Shares and no Ordinary Shares will be held in treasury.
| ||||||||||||||||||||||||||||||||||||||||||||||||
CAPITAL TO BE RAISED ON ADMISSION (AND/OR SECONDARY OFFERING) AND ANTICIPATED MARKET CAPITALISATION ON ADMISSION: | ||||||||||||||||||||||||||||||||||||||||||||||||
Expected Market Capitalisation: TBC
| ||||||||||||||||||||||||||||||||||||||||||||||||
PERCENTAGE OF AIM SECURITIES NOT IN PUBLIC HANDS AT ADMISSION: | ||||||||||||||||||||||||||||||||||||||||||||||||
TBC
| ||||||||||||||||||||||||||||||||||||||||||||||||
DETAILS OF ANY OTHER EXCHANGE OR TRADING PLATFORM TO WHICH THE AIM SECURITIES (OR OTHER SECURITIES OF THE COMPANY) ARE OR WILL BE ADMITTED OR TRADED: | ||||||||||||||||||||||||||||||||||||||||||||||||
Euronext Growth
| ||||||||||||||||||||||||||||||||||||||||||||||||
FULL NAMES AND FUNCTIONS OF DIRECTORS AND PROPOSED DIRECTORS (underlining the first name by which each is known or including any other name by which each is known): | ||||||||||||||||||||||||||||||||||||||||||||||||
Directors Cathal Friel, Executive Chairman Brendan Buckley, Non-executive Director
Proposed Directors Dr Trevor Phillips, Chief Executive Officer Dr Mark Warne, Non-executive Director Michael Meade, Non-executive Director
| ||||||||||||||||||||||||||||||||||||||||||||||||
FULL NAMES AND HOLDINGS OF SIGNIFICANT SHAREHOLDERS EXPRESSED AS A PERCENTAGE OF THE ISSUED SHARE CAPITAL, BEFORE AND AFTER ADMISSION (underlining the first name by which each is known or including any other name by which each is known): | ||||||||||||||||||||||||||||||||||||||||||||||||
Before Admission:
After Admission:
| ||||||||||||||||||||||||||||||||||||||||||||||||
NAMES OF ALL PERSONS TO BE DISCLOSED IN ACCORDANCE WITH SCHEDULE 2, PARAGRAPH (H) OF THE AIM RULES: | ||||||||||||||||||||||||||||||||||||||||||||||||
n/a
| ||||||||||||||||||||||||||||||||||||||||||||||||
(i) ANTICIPATED ACCOUNTING REFERENCE DATE (ii) DATE TO WHICH THE MAIN FINANCIAL INFORMATION IN THE ADMISSION DOCUMENT HAS BEEN PREPARED (this may be represented by unaudited interim financial information) (iii) DATES BY WHICH IT MUST PUBLISH ITS FIRST THREE REPORTS PURSUANT TO AIM RULES 18 AND 19: | ||||||||||||||||||||||||||||||||||||||||||||||||
(i) 31 December (ii) 31 December 2019 (iii) 31 December 2019 due 30 June 2020, 30 June 2020 due September 2020, 31 December 2020 due 30 June 2021
| ||||||||||||||||||||||||||||||||||||||||||||||||
EXPECTED ADMISSION DATE: | ||||||||||||||||||||||||||||||||||||||||||||||||
20 January 2020
| ||||||||||||||||||||||||||||||||||||||||||||||||
NAME AND ADDRESS OF NOMINATED ADVISER: | ||||||||||||||||||||||||||||||||||||||||||||||||
Arden Partners plc 125 Old Broad Street London EC2N 1AR
| ||||||||||||||||||||||||||||||||||||||||||||||||
NAME AND ADDRESS OF BROKER: | ||||||||||||||||||||||||||||||||||||||||||||||||
Arden Partners plc 125 Old Broad Street London EC2N 1AR
| ||||||||||||||||||||||||||||||||||||||||||||||||
OTHER THAN IN THE CASE OF A QUOTED APPLICANT, DETAILS OF WHERE (POSTAL OR INTERNET ADDRESS) THE ADMISSION DOCUMENT WILL BE AVAILABLE FROM, WITH A STATEMENT THAT THIS WILL CONTAIN FULL DETAILS ABOUT THE APPLICANT AND THE ADMISSION OF ITS SECURITIES: | ||||||||||||||||||||||||||||||||||||||||||||||||
A copy of the admission document containing full details about the applicant and the admission of its securities is available on the Company's website, www.openorphan.com
| ||||||||||||||||||||||||||||||||||||||||||||||||
THE CORPORATE GOVERNANCE CODE THE APPLICANT HAS DECIDED TO APPLY | ||||||||||||||||||||||||||||||||||||||||||||||||
The QCA Corporate Governance Code 2018 published by the Quoted Companies Alliance
| ||||||||||||||||||||||||||||||||||||||||||||||||
DATE OF NOTIFICATION: | ||||||||||||||||||||||||||||||||||||||||||||||||
6 January 2020
| ||||||||||||||||||||||||||||||||||||||||||||||||
NEW/ UPDATE: | ||||||||||||||||||||||||||||||||||||||||||||||||
NEW
|
Follow the stocks
